Paclitaxel, doxorubicin regimen better for breast cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1474, 2005-01, pp. : 9-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Doxorubicin more `toxic' than paclitaxel in advanced breast cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 281, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Biweekly paclitaxel plus gemcitabine is a highly active and well tolerated regimen in women with advanced breast cancer

Inpharma, Vol. 1, Iss. 1427, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Paclitaxel and docetaxel in the treatment of breast cancer

By Saloustros Emmanouel Mavroudis Dimitris Georgoulias Vassilis

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2603-2616

Informa Healthcare

Access to resources Recommend Favorite

QOL better with carboplatin + paclitaxel for ovarian cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 498, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer

By Rosanò Laura Cianfrocca Roberta Spinella Francesca Di Castro Valeriana Natali Pier G. Bagnato Anna

Canadian Journal of Physiology and Pharmacology, Vol. 88, Iss. 6, 2010-06 ,pp. : 676-681

NRC Research Press

Access to resources Recommend Favorite